{"id":"placebo-standard-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The placebo component does not have a known mechanism of action, while the standard therapy is a treatment that is already established and widely used.","oneSentence":"This drug is a placebo in combination with standard therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:30.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various conditions"}]},"trialDetails":[{"nctId":"NCT07498166","phase":"NA","title":"Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Achilles Tendon Rupture, Blood Flow Restriction Therapy, Achilles Tendon Repairs/Reconstructions","enrollment":75},{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":"Acute Coronary Syndrome","enrollment":14194},{"nctId":"NCT07149649","phase":"PHASE2, PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT06044935","phase":"NA","title":"Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-01-08","conditions":"Overweight, Obesity","enrollment":100},{"nctId":"NCT07497646","phase":"NA","title":"Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-01-01","conditions":"Chronic Migraine Headache, Chronic Tension-type Headache","enrollment":290},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT07495943","phase":"NA","title":"Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-05-04","conditions":"Fibromyalgia Syndrome, Fibromyalgia","enrollment":200},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07495033","phase":"PHASE3","title":"Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-01","conditions":"CTD-ILD","enrollment":260},{"nctId":"NCT05366855","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","status":"TERMINATED","sponsor":"Vanda Pharmaceuticals","startDate":"2022-04-21","conditions":"Generalized Pustular Psoriasis","enrollment":42},{"nctId":"NCT07496034","phase":"PHASE3","title":"Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial","status":"RECRUITING","sponsor":"Tsai, Chueh-Yi, MD","startDate":"2025-07-01","conditions":"Episodic Migraine","enrollment":40},{"nctId":"NCT03947827","phase":"PHASE3","title":"Minocycline as Adjunctive Treatment for Treatment Resistant Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2020-02-01","conditions":"Treatment Resistant Depression","enrollment":76},{"nctId":"NCT07439666","phase":"NA","title":"NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"Jacques E. Chelly","startDate":"2026-03-31","conditions":"Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA","enrollment":274},{"nctId":"NCT02122185","phase":"PHASE2","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-02-25","conditions":"Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion","enrollment":111},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05500885","phase":"NA","title":"The Clinical Effectiveness of Pulsed Electromagnetic Field Therapy on the Management of Chronic Ankle Instability","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2023-01-02","conditions":"Chronic Ankle Instability","enrollment":62},{"nctId":"NCT07353671","phase":"PHASE2, PHASE3","title":"Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-01","conditions":"Radiation-induced Dermatitis","enrollment":60},{"nctId":"NCT07492875","phase":"PHASE3","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis","enrollment":10},{"nctId":"NCT07474831","phase":"NA","title":"Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2026-03-23","conditions":"Recurrent Bacterial Vaginosis","enrollment":156},{"nctId":"NCT07311512","phase":"NA","title":"PMPR and Chlorhexidine on Periodontal Disease and Vascular Function","status":"RECRUITING","sponsor":"Mahdi Mutahar","startDate":"2026-01-23","conditions":"Periodontal Disease (PD), Cardio Vascular Disease, Oral-Systemic Link","enrollment":30},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":"Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":606},{"nctId":"NCT05722522","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-10","conditions":"Rotator Cuff Tendinopathy","enrollment":33},{"nctId":"NCT07193784","phase":"NA","title":"Effect of Reiki Applied After Coronary Angiography on Pain and Comfort Level","status":"COMPLETED","sponsor":"Mersin University","startDate":"2025-07-15","conditions":"Coronary Angiography","enrollment":85},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT07448519","phase":"NA","title":"Colonic Delivery of DIM and Perilla Oil on Gut Hormones and Food Intake in Obesity","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2023-06-13","conditions":"Obesity & Overweight, Appetite Regulation","enrollment":20},{"nctId":"NCT07489547","phase":"PHASE2, PHASE3","title":"Medication Withdrawal in Stable HF With Improved LVEF","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-03-01","conditions":"Heart Failure","enrollment":90},{"nctId":"NCT07362446","phase":"PHASE2","title":"Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Nyrada Pty Ltd","startDate":"2026-04-16","conditions":"Myocardial Infarction, Reperfusion Injury, AMI","enrollment":300},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT06388941","phase":"PHASE2","title":"Iptacopan in Patients With ANCA Associated Vasculitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-05","conditions":"Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis","enrollment":84},{"nctId":"NCT06587945","phase":"PHASE4","title":"Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","status":"RECRUITING","sponsor":"Center for Eye Research Australia","startDate":"2025-09-19","conditions":"Retinal Detachment","enrollment":144},{"nctId":"NCT06632600","phase":"PHASE2","title":"A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-28","conditions":"Chagas Disease","enrollment":130},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07487246","phase":"PHASE2","title":"Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-05-01","conditions":"Pain Management, Abortion, Second Trimester Abortion","enrollment":76},{"nctId":"NCT07276282","phase":"PHASE3","title":"Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction","status":"RECRUITING","sponsor":"ECRI bv","startDate":"2025-12-19","conditions":"Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery","enrollment":332},{"nctId":"NCT07393360","phase":"NA","title":"Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment","status":"RECRUITING","sponsor":"Pharmanutra S.p.a.","startDate":"2025-12-11","conditions":"Obesity & Overweight","enrollment":144},{"nctId":"NCT07412756","phase":"PHASE3","title":"A Study of Brenipatide in Adult Participants With Major Depressive Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-09","conditions":"Depressive Disorder, Major","enrollment":1000},{"nctId":"NCT07485842","phase":"PHASE4","title":"FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-04","conditions":"Chronic Endometritis","enrollment":300},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT07241390","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-01","conditions":"Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease","enrollment":7140},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT04763343","phase":"PHASE3","title":"Ketamine Treatment of Youth Suicide Attempters","status":"RECRUITING","sponsor":"Tatiana Falcone, MD","startDate":"2022-06-27","conditions":"Suicide, Attempted","enrollment":60},{"nctId":"NCT07284849","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-05","conditions":"CRC (Colorectal Cancer)","enrollment":700},{"nctId":"NCT02664740","phase":"PHASE1, PHASE2","title":"Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2026-09-01","conditions":"Diabetic Foot, Staphylococcal Infections","enrollment":60},{"nctId":"NCT07355218","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus","enrollment":202},{"nctId":"NCT05268289","phase":"PHASE2","title":"Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-10","conditions":"Lupus Nephritis","enrollment":240},{"nctId":"NCT07485296","phase":"PHASE2","title":"Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-01-27","conditions":"Head & Neck Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT06237452","phase":"PHASE3","title":"VE303 for Prevention of Recurrent Clostridioides Difficile Infection","status":"RECRUITING","sponsor":"Vedanta Biosciences, Inc.","startDate":"2024-05-20","conditions":"Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence","enrollment":852},{"nctId":"NCT07332481","phase":"PHASE3","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","status":"NOT_YET_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)","enrollment":202},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT06870409","phase":"PHASE3","title":"Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","status":"RECRUITING","sponsor":"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","startDate":"2025-02-05","conditions":"Endocarditis, Bacterial","enrollment":30},{"nctId":"NCT07207811","phase":"PHASE3","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-10-02","conditions":"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","enrollment":1280},{"nctId":"NCT03596047","phase":"NA","title":"Radial Shockwave Therapy for Erectile Dysfunction","status":"COMPLETED","sponsor":"Boston Medical Group","startDate":"2018-04-19","conditions":"Erectile Dysfunction","enrollment":80},{"nctId":"NCT04944836","phase":"PHASE2","title":"Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-03-09","conditions":"Rotator Cuff Tears","enrollment":58},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT06340958","phase":"PHASE2","title":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","status":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","startDate":"2024-03-18","conditions":"Adjunctive Treatment of Major Depressive Disorder (MDD)","enrollment":99},{"nctId":"NCT06455449","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-20","conditions":"Polymyositis, Dermatomyositis","enrollment":240},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT06732388","phase":"PHASE2","title":"Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-16","conditions":"Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":64},{"nctId":"NCT04899908","phase":"PHASE2","title":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-15","conditions":"Brain Cancer, Brain Metastases, Melanoma","enrollment":134},{"nctId":"NCT06795893","phase":"","title":"The Anifrolumab PRIM Program","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-07","conditions":"Systemic Lupus Erythematosus","enrollment":240},{"nctId":"NCT06318403","phase":"PHASE2","title":"Estradiol Supplementation and Rotator Cuff Repair","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2028-03","conditions":"Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Syndrome","enrollment":58},{"nctId":"NCT05126277","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-14","conditions":"Lupus Nephritis","enrollment":462},{"nctId":"NCT06165445","phase":"NA","title":"Optimizing tDCS Protocol for Clinical Use in Major Depressive Disorder","status":"COMPLETED","sponsor":"The National Brain Mapping Laboratory (NBML)","startDate":"2021-06-01","conditions":"Depressive Disorder, Cognitive Impairment, Psychiatric Disorder","enrollment":60},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07481032","phase":"NA","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-04-01","conditions":"Cirrhosis, Liver, Hepatocellular Carcinoma (HCC), HEPATITIS B CHRONIC","enrollment":1034},{"nctId":"NCT05962606","phase":"PHASE2","title":"Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.","status":"COMPLETED","sponsor":"Aptarion Biotech AG","startDate":"2024-02-02","conditions":"Community-acquired Pneumonia","enrollment":150},{"nctId":"NCT07478328","phase":"PHASE2","title":"Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Longhua Hospital","startDate":"2026-03-08","conditions":"Ischemic Heart Disease","enrollment":60},{"nctId":"NCT07188805","phase":"PHASE3","title":"A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-11-19","conditions":"Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)","enrollment":111},{"nctId":"NCT07477782","phase":"PHASE2","title":"Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05","conditions":"Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)","enrollment":72},{"nctId":"NCT02504372","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":1177},{"nctId":"NCT05688956","phase":"NA","title":"Protein Supplement and Exercise Training for the Treatment of Sarcopenia Risk in Older Adults","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2023-02-01","conditions":"Sarcopenia","enrollment":46},{"nctId":"NCT07241585","phase":"NA","title":"Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-05-01","conditions":"Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":54},{"nctId":"NCT07036523","phase":"PHASE2","title":"A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-11-13","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":71},{"nctId":"NCT05487885","phase":"PHASE4","title":"Anhedonia, Development, and Emotions: Phenotyping and Therapeutics","status":"COMPLETED","sponsor":"Erika Forbes","startDate":"2022-07-22","conditions":"Depression, Anhedonia","enrollment":123},{"nctId":"NCT04512235","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-11-03","conditions":"AL Amyloidosis","enrollment":281},{"nctId":"NCT04504825","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-08-25","conditions":"AL Amyloidosis","enrollment":125},{"nctId":"NCT06659029","phase":"","title":"Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-01","conditions":"Systemic Lupus Erythematosus","enrollment":442},{"nctId":"NCT07473076","phase":"NA","title":"REgulating Pain Through Neurofeedback in infLammatory Bowel diseasE and Musculoskeletal Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-02-25","conditions":"Inflammatory Bowel Diseases","enrollment":80},{"nctId":"NCT05753007","phase":"PHASE2","title":"A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients","status":"TERMINATED","sponsor":"Mclean Hospital","startDate":"2024-02-15","conditions":"Glioblastoma","enrollment":2},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT06913647","phase":"PHASE2","title":"Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-01","conditions":"ESRD, CKD (Chronic Kidney Disease) Stage 5D","enrollment":30},{"nctId":"NCT07475065","phase":"PHASE2, PHASE3","title":"The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy","status":"NOT_YET_RECRUITING","sponsor":"Universitas Sebelas Maret","startDate":"2026-03-01","conditions":"Diabetic Polyneuropathy, Peripheral Nervous System Diseases, Peripheral Neuropathy","enrollment":34},{"nctId":"NCT06570213","phase":"EARLY_PHASE1","title":"Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-04-01","conditions":"PTSD","enrollment":270},{"nctId":"NCT06741969","phase":"PHASE3","title":"Nipocalimab in Moderate to Severe Sjogren's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-04","conditions":"Sjogrens Syndrome","enrollment":655},{"nctId":"NCT04175600","phase":"PHASE3","title":"A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-01-16","conditions":"Hypertension, Pulmonary","enrollment":138},{"nctId":"NCT07438496","phase":"PHASE3","title":"A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-03-05","conditions":"Lupus Erythematosus, Systemic","enrollment":600},{"nctId":"NCT07373210","phase":"NA","title":"Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03","conditions":"Periacetabular Osteotomy, Opiates","enrollment":64},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT07471698","phase":"PHASE1, PHASE2","title":"hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"Help Therapeutics","startDate":"2026-10-20","conditions":"Ischemic Heart Failure, CABG-patients","enrollment":16},{"nctId":"NCT07227454","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-08","conditions":"Depressive Disorder, Major","enrollment":258},{"nctId":"NCT05702034","phase":"PHASE3","title":"A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-15","conditions":"Ischemic Stroke; Ischemic Attack, Transient","enrollment":15000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo+Standard Therapy","genericName":"Placebo+Standard Therapy","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo in combination with standard therapy. Used for Various conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}